Evidence map›Paper›PMID 40879674›Full record

ArticlePediatric cardiology2026

The Effect of Secondary Prophylaxis Adherence on Rheumatic Heart Disease and Determinants of Poor Adherence in Children: A 10-Year Retrospective Cohort Study.

Ipek Ulkersoy, Fatih Karagozlu, Yusuf Iskender Coskun, Nujin Ulug Murt, Mehmet Yildiz, Fatih Haslak, Reyhan Dedeoglu, Ozgur Kasapcopur, Funda Oztunc

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Epigenetic advances in rheumatic heart disease.Journal of translational autoimmunity · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ipek UlkersoyDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-4517-0148
Fatih KaragozluDepartment of Pediatric Cardiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Kocamustafapasa Street No: 53, 34098, Fatih, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-6861-8163
Yusuf Iskender CoskunDepartment of Pediatric Cardiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Kocamustafapasa Street No: 53, 34098, Fatih, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-4127-6946
Nujin Ulug MurtDepartment of Pediatric Cardiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Kocamustafapasa Street No: 53, 34098, Fatih, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-3748-8671
Mehmet YildizDepartment of Pediatric Rheumatology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-7834-4909
Fatih HaslakDepartment of Pediatric Rheumatology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-6963-9668
Reyhan DedeogluDepartment of Pediatric Cardiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Kocamustafapasa Street No: 53, 34098, Fatih, Istanbul, Turkey. reyhan.dedeoglu@iuc.edu.tr.ORCID http://orcid.org/0000-0002-5600-7899
Ozgur KasapcopurDepartment of Pediatric Rheumatology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-1125-7720
Funda OztuncDepartment of Pediatric Cardiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Kocamustafapasa Street No: 53, 34098, Fatih, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-6921-917X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatic heart disease (RHD) remains the leading cause of acquired cardiovascular morbidity and mortality in children. Since secondary prophylaxis is the cornerstone of the management of acute rheumatic fever (ARF) and RHD, this study aimed to assess the impact of prophylaxis adherence on disease recurrence and cardiac outcomes and to identify causes of non-adherence with prophylaxis. We retrospectively reviewed 137 ARF cases diagnosed before the age of 18 years, with a minimum follow-up duration of ≥ 6 months. Diagnosis was based on the Revised Jones criteria. Clinical and echocardiographic evaluations were conducted to assess RHD, and prophylaxis adherence was evaluated through qualitative interviews. The cohort (49% female, mean age 13.97 ± 3.69 years) had a 43.8% rate of cardiac involvement at diagnosis, decreasing to 40.9% at last follow-up, with 38% developing RHD. RHD development was significantly associated with initial carditis presence and worse severity (p = 0.001; p = 0.046). Adherence to secondary prophylaxis was observed in 88.3% (n = 121). Low socioeconomic status, milder valvulitis at diagnosis, and longer follow-up duration were associated with non-adherence (p = 0.008; 0.041; 0.001). Adherent patients showed significant reductions in both the number of affected valves (p = 0.001) and severity of valvular regurgitation (p = 0.003). Recurrence was more frequent among non-adherent patients (p = 0.005). Non-adherence to secondary prophylaxis remains a major barrier in ARF/RHD control, as it correlates with more severe valvular involvement and recurrence. Identifying factors influencing adherence may guide future strategies to improve both prophylaxis adherence and long-term outcomes.

Indexed as

Anti-Bacterial AgentsRheumatic Heart DiseaseSecondary PreventionAdolescentChildEchocardiographyFemaleFollow-Up StudiesHumansMaleRecurrenceRetrospective StudiesAnti-Bacterial AgentsAcute rheumatic feverRheumatic heart diseaseSecondary prophylaxisTreatment adherence

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.